Protein degradation, also known as proteolysis, refers to a set of enzymatic reactions by which the proteins are broken down into smaller polypeptides or amino acids by protease. Proteolysis may also occur in some special conditions that are absent from the enzymes, such as mineral acids and high temperatures. Proteolysis includes two main pathways: ubiquitin-mediated proteolysis and lysosomal proteolysis.
Ubiquitin mediated proteolysis is the process by which ubiquitin binds covalently to the target protein and degrades the target protein. The ubiquitination and subsequent degradation process of target proteins run through the plasma membrane system of the entire cell, from the cell membrane to the endoplasmic reticulum to the nuclear membrane.
The ubiquitin-proteasome pathway is an important protein quality control system in eukaryotic cells. Proteolysis by ubiquitin-proteasome pathway regulates the cell cycle, cell proliferation ＆ differentiation, signal transduction, and other cellular physiological processes. And intracellular ubiquitin-mediated proteolysis is one of the most important post-transcriptional modifications of proteins.
In the pathway of ubiquitin-mediated proteolysis, the substrate protein binds to ubiquitin by ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, and ubiquitin ligase E3. Ubiquitin, a small protein, functions as a marker for marking the substrate for degradation by the proteasome (26s proteasome).
The ubiquitination of target proteins is a consuming-ATP process. First, E1 catalyzes the adenylation of ubiquitin's C-terminal. Activated ubiquitin transfers to the Cys residues of E1 and subsequently get molecular rearrangement to form intramolecular thioester bonds. Secondly, the E1-ubiquitin complex transfers ubiquitin to the E2 by transacylation. Finally, the ubiquitin ligase E3 binds to the target protein and specifically recognizes E2. And then the target protein binds to the ubiquitin linked to the E2 enzyme. The process means the ubiquitination of the target protein is finished.
When the first ubiquitin molecule is linked to the target protein under the catalysis of E3, other ubiquitin molecules are also successively linked to the Lys residue of the previous ubiquitin molecule to form a polyubiquitin chain. The formation of polyubiquitin chains is a signal for protein degradation. And studies have found that a novel ubiquitin chain transfer factor E4 (Ufd2p) can convert non-degradable ubiquitin chain signals into degraded ubiquitin chain signals. Degraded ubiquitin chain signals can be recognized by the proteasome, which promotes the degradation of modified substrate proteins.
The 26s proteasome consists of two circular 19s subunits and one microsomal 20s subunit. After the ubiquitin-protein conjugate interacts with the 19s ubiquitin receptor of the 26s proteasome, the protein substrate is unfolded. The unfolded protein substrate enters the 20s core particle through the proteasome receptor end crevice, where the substrate protein is cleaved multiple times and forms a peptide of 3-22 amino acid residues. Under the action of ubiquitin and oligopeptidase, the polyubiquitin chain is reduced to monomer for the next round of protein degradation.
Because proteins associated with diseases are commonly used as substrates in the ubiquitin degradation pathway. And abnormal ubiquitin-mediated proteolysis could cause an increased or reduced rate of degradation. Therefore, if the ubiquitin metabolic pathway is abnormal, it will lead to a variety of diseases.
Malignant tumors are often related to the expression of oncogenes and tumor suppressor gene products. When growth factors that cause tumors fail to degrade in the ubiquitin-proteasome system, it normally triggers tumors.
For the nervous system, alterations in its substrate homeostasis cause a significant decrease in the excited excitatory junction potential. Studies on Drosophila neuromuscular junctions have shown that overexpression of the faf gene (in the ubiquitinase family) in the ubiquitin system leads to synaptic overgrowth and neurotransmitter release disorders. Angelman syndrome is caused by a lack of a gene encoding E6-AP or an abnormal function of E6-AP protease.
|HERC2||HERC2 Antibody||HERC2 Protein||HERC2 ELISA Kit|
|HERC3||HERC3 Antibody||HERC3 Protein||HERC3 ELISA Kit|
|HERC4||HERC4 Antibody||HERC4 Protein||HERC4 ELISA Kit|
|HUWE1||HUWE1 Antibody||HUWE1 Protein||HUWE1 ELISA Kit|
|ITCH||ITCH Antibody||ITCH Protein||ITCH ELISA Kit|
|KEAP1||KEAP1 Antibody||KEAP1 Protein||KEAP1 ELISA Kit|
|KLHL13||KLHL13 Antibody||KLHL13 Protein||KLHL13 ELISA Kit|
|MAP3K1||MAP3K1 Antibody||MAP3K1 Protein||MAP3K1 ELISA Kit|
|MDM2||MDM2 Antibody||MDM2 Protein||MDM2 ELISA Kit|
|MGRN1||MGRN1 Antibody||MGRN1 Protein||MGRN1 ELISA Kit|
|MID1||MID1 Antibody||MID1 Protein||MID1 ELISA Kit|
|NEDD4||NEDD4 Antibody||NEDD4 Protein||NEDD4 ELISA Kit|
|NEDD4L||NEDD4L Antibody||NEDD4L Protein||NEDD4L ELISA Kit|
|NHLRC1||NHLRC1 Antibody||NHLRC1 Protein||NHLRC1 ELISA Kit|
|PIAS1||PIAS1 Antibody||PIAS1 Protein||PIAS1 ELISA Kit|
|PIAS2||PIAS2 Antibody||PIAS2 Protein||PIAS2 ELISA Kit|
|PIAS3||PIAS3 Antibody||PIAS3 Protein||PIAS3 ELISA Kit|
|PIAS4||PIAS4 Antibody||PIAS4 Protein||PIAS4 ELISA Kit|
|PML||PML Antibody||PML Protein||PML ELISA Kit|
|PPIL2||PPIL2 Antibody||PPIL2 Protein||PPIL2 ELISA Kit|